A Fragmented Adeno-Associated Viral Dual Vector Strategy for Treatment of Diseases Caused by Mutations in Large Genes Leads to Expression of Hybrid Transcripts
Open accessAbstract
Objective: Dual vector AAV systems are being utilised to enable gene therapy for disorders in which the disease gene is too large to fit into a single capsid.Fragmented adeno-associated viral (fAAV) vectors containing single inverted terminal repeat truncated transgenes have been considered as one such gene replacement strategy.Here we aim to add to the current understanding of the molecular mechanisms employed by fAAV dual vector systems.Methods: Oversized (>8 kb) transgene constructs containing ABCA4 coding sequence were packaged as truncated fragments <5 kb in size into various AAV serotypes.In vitro transductions with these fAAV vector preparations were conducted with mRNA and protein expression products assessed by way of RT-PCR, qPCR and western blot techniques.Results: Transductions with fAAV vector preparations yielded ABCA4 mRNA, but did not generate detectable levels of protein.Sequencing of the transcript population revealed the presence of full length ABCA4 CDS with additional hybrid ABCA4 variants, indicating truncated transgenes without regions of overlap were joining and forming stable hybrid transgenes.In contrast, an ABCA4 overlapping dual vector system (OV) with a defined complementary region generated only full length mRNA transcripts plus detectable ABCA4 protein.Conclusion: Despite previous success shown with the fAAV approach, the lack of repeatability and identification of stable hybrid transcripts capable of protein production suggests there is more refinement required before considering this approach in a clinical setting.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Low transduction efficiencies and aberrant production of truncated proteins from single AAV vectors have been two major limitations.
“the low transduction efficiencies as well as the aberrant production of truncated proteins from single AAV vectors have been two major limitations [103,104]”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [104]
The Discussion (page unavailable) describes the fragmented dual-vector approach as less efficient than other dual-vector methods and predicts that its hybrid transcripts could produce truncated proteins if translated. It does not establish low transduction efficiency for single AAV vectors or demonstrate aberrant production of truncated proteins; the Introduction says translation was not detectable by western blot. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,025 · cited 2× · see citing works
“Given that the fAAV approach will generate a heterogeneous transgene population [3-5], we performed further in vitro transduction experiments to discover what these truncated transgenes would initiate once inside cells.”
BackgroundGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419 · cited 1× · see citing works
“Adeno-associated virus (AAV) vectors are known to have an optimal packaging capacity of ~4.7 kb (the size of their native genome) but can be encouraged to package slightly larger transgenes [1].”
BackgroundInfluentialAllocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · cited 3× · see citing works
“In 2008, Allocca et al. [2] attempted to package much larger genomes of up to 8.9 kb and given the positive outcomes of their strategy, assumed the packaging to have been successful.”
BackgroundInfluentialEffective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269 · see citing works
Characterization of Genome Integrity for Oversized Recombinant AAV Vector
Dong, B., Nakai, H., & Xiao, W. (2010) · Molecular Therapy · doi:10.1038/mt.2009.258 · Cited by 230 · cited 4× · see citing works
“is now acknowledged to be due to AAV capsids truncating the oversized transgenes during the packaging process [5].”
BackgroundMethodInfluentialNakai, H., Storm, T. A., & Kay, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9451-9463.2000 · Cited by 194 · cited 2× · see citing works
“Within the host nucleus these have been predicted to regenerate the original oversized transgene through homologous recombination [7] or annealing of plus and minus strand complementary regions prior to second-strand synthesis [8], Trapani et al. have shown success with the fAAV approach in HEK293…”
BackgroundEvidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb
Lai, Y., Yue, Y., & Duan, D. (2010) · Molecular Therapy · doi:10.1038/mt.2009.256 · Cited by 166 · see citing works
The Role of DNA-PKcs and Artemis in Opening Viral DNA Hairpin Termini in Various Tissues in Mice
Inagaki, K., Ma, C.-R., Storm, T. A., Kay, M., & Nakai, H. (2007) · Journal of Virology · doi:10.1128/jvi.01225-07 · Cited by 76 · cited 4× · see citing works
“…synthesis [8], Trapani et al. have shown success with the fAAV approach in HEK293 cells [9] and Hirsch et al. suggested fAAV vectors are a better gene therapy approach for delivering large genes to the retina and skeletal muscle than an alternative trans-splicing dual vector approach [10].”
BackgroundInfluentialGrose, W. E., Clark, K. R., Griffin, D., Malik, V., Shontz, K. M., Montgomery, C. L., Lewis, S., Brown, R. H., Janssen, P. M. L., Mendell, J. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039233 · Cited by 76 · see citing works
Oversized AAV Transductifon Is Mediated via a DNA-PKcs-independent, Rad51C-dependent Repair Pathway
Hirsch, M. L., Li, C., Bellon, I., Yin, C., Chavala, S., Pryadkina, M., Richard, I., & Samulski, R. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.184 · Cited by 62 · cited 2× · see citing works
“have shown success with the fAAV approach in HEK293 cells [9] and Hirsch et al.”
BackgroundMethodNative Molecular State of Adeno-Associated Viral Vectors Revealed by Single-Molecule Sequencing
Kapranov, P., Chen, L., Dederich, D. A., Dong, B., He, J., Steinmann, K. E., Moore, A. R., Thompson, J. F., Milos, P. M., & Xiao, W. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.160 · Cited by 58 · cited 1× · see citing works
“This method provides no designated limit of packaging at the 5’ end of either the plus or minus strands of the transgene and results in a collection of AAV particles carrying transgenes of different length containing only a single ITR, referred to herein as fragmented AAV (fAAV) [5,6].”
MethodPryadkina, M., Lostal, W., Bourg, N., Charton, K., Roudaut, C., Hirsch, M. L., & Richard, I. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.9 · Cited by 53 · cited 1× · see citing works
“The mechanisms by which transgenes recombine are still being elucidated but both non-homologous end joining (NHEJ) [11] and homologous recombination [10] has been implicated.”
BackgroundHalbert, C. L., Metzger, M. J., Lam, S.-L., & Miller, A. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.167 · Cited by 34 · cited 3× · see citing works
“Packaging fragmented single-ITR AAV genomes from over-sized transgenes has been shown by several research groups to successfully lead to expression of the target protein in transduced cells in vitro and in vivo with proof of principle demonstrated in muscle, lung and retina [2,7,9,10,12].”
Background
Flagged first, then by citations
2 of the 15 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92 · see citing works
Self-citationMarrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56 · see citing works
“transduction efficiencies as well as the aberrant production of truncated proteins from single AAV vectors have been two major limitations [103,104].”
BackgroundDyka, F. M., Molday, L. L., Chiodo, V. A., Molday, R. S., & Hauswirth, W. W. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.132 · Cited by 56 · see citing works
“In addition, these sorts of fragmented transgenes present the clear risk of imperfect reconstitution of the normal coding sequence upon exposure to the cellular DNA doublestrand break repair machinery.(33) To overcome these drawbacks for cDNAs exceeding the size limit of AAV vectors, dual vector strategies for oversiz…”
BackgroundTherapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49 · see citing works
Self-citationWagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 48 · see citing works
Split AAV8 Mediated ABCA4 Expression for Gene Therapy of Mouse Stargardt Disease (STGD1)
Li, R., Jing, Q., She, K., Wang, Q., Jin, X., Zhao, Q., Su, J., Song, L., Fu, J., Wu, X., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.017 · Cited by 21 · see citing works
The ABCs of Stargardt disease: the latest advances in precision medicine
Zaydon, Y. A., & Tsang, S. H. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01272-y · Cited by 17 · see citing works
“Further assessments showed that the fragmented AAV-ABCA4 vectors could recombine to create the full ABCA4 gene transcript but generated hybrid transcripts with unintentional AAV genome integrations [44].”
BackgroundAdvances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
Mnyandu, N., Limani, S. W., Arbuthnot, P. B., & Maepa, M. B. (2021) · Virology Journal · doi:10.1186/s12985-021-01715-9 · Cited by 9 · see citing works
Fehrman, R. L., Chern, K. J., Stoltz, K. P., & Lipinski, D. M. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110223 · Cited by 5 · see citing works
Precision Is Not Enough: When Tools Outpace Translation in Ocular Gene Therapy
Elsayed, M. E. A. A., & MacLaren, R. E. (2026) · Genes · doi:10.3390/genes17030283 · Cited by 1 · see citing works
“Investigators have explored dual-AAV systems to reconstitute large genes in situ or have turned to alternative vectors, but efficient and consistent reassembly remains challenging [69–71].”
Self-citationFehrman, R. L., & Lipinski, D. M. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.11.38 · Cited by 2 · see citing works
- Authors
- McClements, M. E., Charbel Issa, P., Blouin, V., & MacLaren, R. E.
- Affiliations
- University of Oxford (GB)
- John Radcliffe Hospital (GB)
- Venue
- Journal of Genetic Syndromes & Gene Therapy
- Publisher
- OMICS Publishing Group
- Published
- 2016
- Volume
- 7
- Issue
- 5
- Pages
- 311
- ISSN
- 2157-7412 (ISSN-L)
- PMC
- PMC5321474
- OpenAlex
- W2549063601
- Cited by
- 13
- References
- 15
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2021: 4 · 2019: 2 · 2018: 1 · 2017: 1
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Journal of Genetic Syndromes & Gene Therapy (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (NF-SI-0515-10047)
- Medical Research Council (MR/K007629/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
- Keywords
- ABCA4, gene therapy vectors, transgene expression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review